Rayence Co

Rayence Co EBIT per Share

The EBIT per Share of Rayence Co (228850.KQ) as of Nov 14, 2026 is -251.03 KRW. In the previous year, EBIT per Share was 421.41 KRW — a change of -159.57% (lower).

EBIT per Share

-251.03KRW

YoY

-159.57%

Last updated:

EBIT per Share of Rayence Co is 2025 -251.03 KRW. EBIT per Share of Rayence Co was 2024 421.41 KRW. It decreases by -159.57% lower compared to the previous year.

The Rayence Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
102.30 KRW
Jan 1, 2021
1,300.52 KRW
Jan 1, 2022
1,399.83 KRW
Jan 1, 2023
1,229.32 KRW
Jan 1, 2024
421.41 KRW
Jan 1, 2025
-251.03 KRW
Jan 1, 2026 (e)
282.40 KRW
Jan 1, 2027 (e)
449.28 KRW
The Rayence Co EBIT per Share history
YEAREBIT per ShareYoY
est449.28KRW+59.09%
est282.40KRW-212.50%
-251.03KRW-159.57%
421.41KRW-65.72%
1,229.32KRW-12.18%
1,399.83KRW+7.64%
1,300.52KRW+1,171.30%
102.30KRW-91.61%
1,219.34KRW+5.14%
1,159.69KRW+7.50%
1,078.77KRW-2.19%
1,102.91KRW-27.30%
1,517.18KRW+78.22%
851.31KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

EBIT per Share of Rayence Co is -251.03 KRW in 2025.

EBIT per Share of Rayence Co changed from 421.41 KRW to -251.03 KRW, representing a -159.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Rayence Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Rayence Co

All Key Metrics — Rayence Co